Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-CART-007 in CD7+ Hematologic Malignancies
NCT05377827Phase 1Suspended
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of soficabtagene geleucel in acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (4 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Recommended phase II dose at Day 42, Complete metabolic response or partial metabolic response at 24 months and 1 more. Started Oct 2023; status: suspended.
02
Drugs
soficabtagene geleucel
03
Conditions
acute myeloid leukemia (AML)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05377827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377827.